Hershel Patel1, Lauren J Jeang1, Ankit Shah2, Edgar M Espana1,3, Curtis E Margo1,4. 1. Department of Ophthalmology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. 2. Department of Ophthalmology, University of Florida College of Medicine, Gainesville, Florida, USA. 3. Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. 4. Department of Pathology and Cell Biology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Abstract
PURPOSE: To emphasize the importance of staging ocular surface squamous neoplasia when contemplating use of topical interferon alpha-2b alone. CASES: Two patients with 360 degrees of limbal involvement. RESULTS: Two patients with in situ squamous cell carcinoma of the conjunctiva and clinical involvement of the entire limbus were treated with topical interferon alpha-2b. Thorough examination and multiple biopsies excluded invasive disease. The patients had complete response to therapy. CONCLUSION: Widespread intraepithelial squamous neoplasia involving the entire limbus can be successfully treated with topical therapies. Biopsy plays a role in excluding invasive disease. Interferon alpha-2b is a preferable agent to start with because it is well tolerated. Since long-term risks of recurrence are unknown, appropriate monitoring is essential.
PURPOSE: To emphasize the importance of staging ocular surface squamous neoplasia when contemplating use of topical interferon alpha-2b alone. CASES: Two patients with 360 degrees of limbal involvement. RESULTS: Two patients with in situ squamous cell carcinoma of the conjunctiva and clinical involvement of the entire limbus were treated with topical interferon alpha-2b. Thorough examination and multiple biopsies excluded invasive disease. The patients had complete response to therapy. CONCLUSION: Widespread intraepithelial squamous neoplasia involving the entire limbus can be successfully treated with topical therapies. Biopsy plays a role in excluding invasive disease. Interferon alpha-2b is a preferable agent to start with because it is well tolerated. Since long-term risks of recurrence are unknown, appropriate monitoring is essential.
Authors: Madhura G Joag; Adam Sise; Juan Carlos Murillo; Ibrahim Osama Sayed-Ahmed; James R Wong; Carolina Mercado; Anat Galor; Carol L Karp Journal: Ophthalmology Date: 2016-03-27 Impact factor: 12.079
Authors: Carol L Shields; Swathi Kaliki; H Jane Kim; Saad Al-Dahmash; Sanket U Shah; Sara E Lally; Jerry A Shields Journal: Cornea Date: 2013-03 Impact factor: 2.651